Impairing Temozolomide Resistance Driven by Glioma Stem-like Cells with adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside - Archive ouverte HAL Access content directly
Journal Articles International Journal of Cancer Year : 2019

Impairing Temozolomide Resistance Driven by Glioma Stem-like Cells with adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside

(1) , (1) , (1, 2) , (3) , (3) , (4) , (5) , (5) , (6, 7, 8) , (9) , (5) , (5) , (5, 10) , (1) , (1, 10) , (1, 2)
1
2
3
4
5
6
7
8
9
10
Catherine Gratas
  • Function : Author
  • PersonId : 1033035
Claire Pecqueur

Abstract

Stem cell chemo-resistance is still challenging the efficacy of the front-line temozolomide against glioblastoma. Novel therapies are urgently needed to fight those cells in order to control tumor relapse. Here, we report that anti-O-acetyl-GD2 adjuvant immunotherapy controls glioma stem-like cell-driven chemo-resistance. Using patient-derived glioblastoma cells we found that glioma stem-like cells over-expressed O-acetyl-GD2. As a result, monoclonal antibody 8B6 immunotherapy significantly increased temozolomide genotoxicity and tumor cell death in vitro by enhancing temozolomide tumor uptake. Furthermore, the combination therapy decreased the expression of the glioma stem-like cell markers CD133 and Nestin and compromised glioma stem-like cell self-renewal capabilities. When tested in vivo, adjuvant 8B6 immunotherapy prevented the extension of the temozolomide-resistant glioma stem-like cell pool within the tumor bulk in vivo and was more effective than the single agent therapies. This is the first report demonstrating that anti-O-acetyl-GD2 monoclonal antibody 8B6 targets glioblastoma in a manner that control temozolomide-resistance driven by glioma stem-like cells. Together our results offer a proof of concept for using anti-O-acetyl GD2 reagents in glioblastoma to develop more efficient combination therapies for malignant gliomas. This article is protected by copyright. All rights reserved.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02168202 , version 1 (28-06-2019)

Identifiers

Cite

Julien Fleurence, Meriem Bahri, Sophie Fougeray, Sébastien Faraj, Sarah Vermeulen, et al.. Impairing Temozolomide Resistance Driven by Glioma Stem-like Cells with adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside: A novel synergistic option for glioblastoma therapy. International Journal of Cancer, In press, Epub ahead of print. ⟨10.1002/ijc.32533⟩. ⟨inserm-02168202⟩
318 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More